Eintrag weiter verarbeiten
Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | Journal of Clinical Oncology, 27, 2009, 13, S. 2199-2208 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Findeisen, Peter Zapatka, Marc Peccerella, Teresa Matzk, Heike Neumaier, Michael Schadendorf, Dirk Ugurel, Selma Findeisen, Peter Zapatka, Marc Peccerella, Teresa Matzk, Heike Neumaier, Michael Schadendorf, Dirk Ugurel, Selma |
|---|---|
| author |
Findeisen, Peter Zapatka, Marc Peccerella, Teresa Matzk, Heike Neumaier, Michael Schadendorf, Dirk Ugurel, Selma |
| spellingShingle |
Findeisen, Peter Zapatka, Marc Peccerella, Teresa Matzk, Heike Neumaier, Michael Schadendorf, Dirk Ugurel, Selma Journal of Clinical Oncology Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling Cancer Research Oncology |
| author_sort |
findeisen, peter |
| spelling |
Findeisen, Peter Zapatka, Marc Peccerella, Teresa Matzk, Heike Neumaier, Michael Schadendorf, Dirk Ugurel, Selma 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2008.18.0554 <jats:sec><jats:title>Purpose</jats:title><jats:p> Currently known prognostic serum biomarkers of melanoma are powerful in metastatic disease, but weak in early-stage patients. This study was aimed to identify new prognostic biomarkers of melanoma by serum mass spectrometry (MS) proteomic profiling, and to validate candidates compared with established markers. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Two independent sets of serum samples from 596 melanoma patients were investigated. The first set (stage I = 102; stage IV = 95) was analyzed by matrix assisted laser desorption and ionization time of flight (MALDI TOF) MS for biomarkers differentiating between stage I and IV. In the second set (stage I = 98; stage II = 91; stage III = 87; stage IV = 103), the serum concentrations of the candidate marker serum amyloid A (SAA) and the known biomarkers S100B, lactate dehydrogenase, and C reactive protein (CRP) were measured using immunoassays. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> MALDI TOF MS revealed a peak at m/z 11.680 differentiating between stage I and IV, which could be identified as SAA. High peak intensities at m/z 11.680 correlated with poor survival. In univariate analysis, SAA was a strong prognostic marker in stage I to III (P = .043) and stage IV (P = .000083) patients. Combination of SAA and CRP increased the prognostic impact to P = .011 in early-stage (I to III) patients. Multivariate analysis revealed sex, stage, tumor load, S100B, SAA, and CRP as independent prognostic factors, with an interaction between SAA and CRP. In stage I to III patients, SAA combined with CRP was superior to S100B in predicting patients' progression-free and overall survival. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> SAA combined with CRP might be used as prognostic serological biomarkers in early-stage melanoma patients, helping to discriminate low-risk patients from high-risk patients needing adjuvant treatment. </jats:p></jats:sec> Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2008.18.0554 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOC4xOC4wNTU0 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOC4xOC4wNTU0 |
| institution |
DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 |
| imprint |
American Society of Clinical Oncology (ASCO), 2009 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2009 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
findeisen2009serumamyloidaasaprognosticmarkerinmelanomaidentifiedbyproteomicprofiling |
| publishDateSort |
2009 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling |
| title_unstemmed |
Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling |
| title_full |
Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling |
| title_fullStr |
Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling |
| title_full_unstemmed |
Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling |
| title_short |
Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling |
| title_sort |
serum amyloid a as a prognostic marker in melanoma identified by proteomic profiling |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2008.18.0554 |
| publishDate |
2009 |
| physical |
2199-2208 |
| description |
<jats:sec><jats:title>Purpose</jats:title><jats:p> Currently known prognostic serum biomarkers of melanoma are powerful in metastatic disease, but weak in early-stage patients. This study was aimed to identify new prognostic biomarkers of melanoma by serum mass spectrometry (MS) proteomic profiling, and to validate candidates compared with established markers. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Two independent sets of serum samples from 596 melanoma patients were investigated. The first set (stage I = 102; stage IV = 95) was analyzed by matrix assisted laser desorption and ionization time of flight (MALDI TOF) MS for biomarkers differentiating between stage I and IV. In the second set (stage I = 98; stage II = 91; stage III = 87; stage IV = 103), the serum concentrations of the candidate marker serum amyloid A (SAA) and the known biomarkers S100B, lactate dehydrogenase, and C reactive protein (CRP) were measured using immunoassays. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> MALDI TOF MS revealed a peak at m/z 11.680 differentiating between stage I and IV, which could be identified as SAA. High peak intensities at m/z 11.680 correlated with poor survival. In univariate analysis, SAA was a strong prognostic marker in stage I to III (P = .043) and stage IV (P = .000083) patients. Combination of SAA and CRP increased the prognostic impact to P = .011 in early-stage (I to III) patients. Multivariate analysis revealed sex, stage, tumor load, S100B, SAA, and CRP as independent prognostic factors, with an interaction between SAA and CRP. In stage I to III patients, SAA combined with CRP was superior to S100B in predicting patients' progression-free and overall survival. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> SAA combined with CRP might be used as prognostic serological biomarkers in early-stage melanoma patients, helping to discriminate low-risk patients from high-risk patients needing adjuvant treatment. </jats:p></jats:sec> |
| container_issue |
13 |
| container_start_page |
2199 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
27 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347986427117570 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:03:59.63Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Serum+Amyloid+A+As+a+Prognostic+Marker+in+Melanoma+Identified+by+Proteomic+Profiling&rft.date=2009-05-01&genre=article&issn=1527-7755&volume=27&issue=13&spage=2199&epage=2208&pages=2199-2208&jtitle=Journal+of+Clinical+Oncology&atitle=Serum+Amyloid+A+As+a+Prognostic+Marker+in+Melanoma+Identified+by+Proteomic+Profiling&aulast=Ugurel&aufirst=Selma&rft_id=info%3Adoi%2F10.1200%2Fjco.2008.18.0554&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347986427117570 |
| author | Findeisen, Peter, Zapatka, Marc, Peccerella, Teresa, Matzk, Heike, Neumaier, Michael, Schadendorf, Dirk, Ugurel, Selma |
| author_facet | Findeisen, Peter, Zapatka, Marc, Peccerella, Teresa, Matzk, Heike, Neumaier, Michael, Schadendorf, Dirk, Ugurel, Selma, Findeisen, Peter, Zapatka, Marc, Peccerella, Teresa, Matzk, Heike, Neumaier, Michael, Schadendorf, Dirk, Ugurel, Selma |
| author_sort | findeisen, peter |
| container_issue | 13 |
| container_start_page | 2199 |
| container_title | Journal of Clinical Oncology |
| container_volume | 27 |
| description | <jats:sec><jats:title>Purpose</jats:title><jats:p> Currently known prognostic serum biomarkers of melanoma are powerful in metastatic disease, but weak in early-stage patients. This study was aimed to identify new prognostic biomarkers of melanoma by serum mass spectrometry (MS) proteomic profiling, and to validate candidates compared with established markers. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Two independent sets of serum samples from 596 melanoma patients were investigated. The first set (stage I = 102; stage IV = 95) was analyzed by matrix assisted laser desorption and ionization time of flight (MALDI TOF) MS for biomarkers differentiating between stage I and IV. In the second set (stage I = 98; stage II = 91; stage III = 87; stage IV = 103), the serum concentrations of the candidate marker serum amyloid A (SAA) and the known biomarkers S100B, lactate dehydrogenase, and C reactive protein (CRP) were measured using immunoassays. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> MALDI TOF MS revealed a peak at m/z 11.680 differentiating between stage I and IV, which could be identified as SAA. High peak intensities at m/z 11.680 correlated with poor survival. In univariate analysis, SAA was a strong prognostic marker in stage I to III (P = .043) and stage IV (P = .000083) patients. Combination of SAA and CRP increased the prognostic impact to P = .011 in early-stage (I to III) patients. Multivariate analysis revealed sex, stage, tumor load, S100B, SAA, and CRP as independent prognostic factors, with an interaction between SAA and CRP. In stage I to III patients, SAA combined with CRP was superior to S100B in predicting patients' progression-free and overall survival. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> SAA combined with CRP might be used as prognostic serological biomarkers in early-stage melanoma patients, helping to discriminate low-risk patients from high-risk patients needing adjuvant treatment. </jats:p></jats:sec> |
| doi_str_mv | 10.1200/jco.2008.18.0554 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOC4xOC4wNTU0 |
| imprint | American Society of Clinical Oncology (ASCO), 2009 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2009 |
| institution | DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T18:03:59.63Z |
| match_str | findeisen2009serumamyloidaasaprognosticmarkerinmelanomaidentifiedbyproteomicprofiling |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 2199-2208 |
| publishDate | 2009 |
| publishDateSort | 2009 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Findeisen, Peter Zapatka, Marc Peccerella, Teresa Matzk, Heike Neumaier, Michael Schadendorf, Dirk Ugurel, Selma 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2008.18.0554 <jats:sec><jats:title>Purpose</jats:title><jats:p> Currently known prognostic serum biomarkers of melanoma are powerful in metastatic disease, but weak in early-stage patients. This study was aimed to identify new prognostic biomarkers of melanoma by serum mass spectrometry (MS) proteomic profiling, and to validate candidates compared with established markers. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Two independent sets of serum samples from 596 melanoma patients were investigated. The first set (stage I = 102; stage IV = 95) was analyzed by matrix assisted laser desorption and ionization time of flight (MALDI TOF) MS for biomarkers differentiating between stage I and IV. In the second set (stage I = 98; stage II = 91; stage III = 87; stage IV = 103), the serum concentrations of the candidate marker serum amyloid A (SAA) and the known biomarkers S100B, lactate dehydrogenase, and C reactive protein (CRP) were measured using immunoassays. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> MALDI TOF MS revealed a peak at m/z 11.680 differentiating between stage I and IV, which could be identified as SAA. High peak intensities at m/z 11.680 correlated with poor survival. In univariate analysis, SAA was a strong prognostic marker in stage I to III (P = .043) and stage IV (P = .000083) patients. Combination of SAA and CRP increased the prognostic impact to P = .011 in early-stage (I to III) patients. Multivariate analysis revealed sex, stage, tumor load, S100B, SAA, and CRP as independent prognostic factors, with an interaction between SAA and CRP. In stage I to III patients, SAA combined with CRP was superior to S100B in predicting patients' progression-free and overall survival. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> SAA combined with CRP might be used as prognostic serological biomarkers in early-stage melanoma patients, helping to discriminate low-risk patients from high-risk patients needing adjuvant treatment. </jats:p></jats:sec> Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling Journal of Clinical Oncology |
| spellingShingle | Findeisen, Peter, Zapatka, Marc, Peccerella, Teresa, Matzk, Heike, Neumaier, Michael, Schadendorf, Dirk, Ugurel, Selma, Journal of Clinical Oncology, Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling, Cancer Research, Oncology |
| title | Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling |
| title_full | Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling |
| title_fullStr | Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling |
| title_full_unstemmed | Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling |
| title_short | Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling |
| title_sort | serum amyloid a as a prognostic marker in melanoma identified by proteomic profiling |
| title_unstemmed | Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2008.18.0554 |